Christopher A Heid1, Mitri K Khoury2, Kayla Maaraoui3, Charles Liu3, Matthias Peltz3, Michael A Wait3, W Steves Ring3, Lynn C Huffman3. 1. Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: christopher.heid@phhs.org. 2. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; Division of Vascular Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin. 3. Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: Cardiopulmonary bypass (CPB) is often used to support patients undergoing lung transplantation who are intolerant of anatomic manipulation or single lung ventilation during the procedure. However, CPB may be associated with adverse outcomes. We evaluated the hypothesis that CPB is associated with increased acute kidney injury (AKI) and postoperative mortality after lung transplantation. MATERIALS AND METHODS: This was a retrospective review of our institutional lung transplant database at the University of Texas Southwestern Medical Center from 2012 to 2018. Patients were grouped based on their need for CPB. The primary outcome was AKI within 48 h of transplantation, which was defined as Kidney Disease Improving Global Outcomes stage 1 or greater. Secondary outcomes included all-cause mortality. RESULTS: A total of 426 patients underwent lung transplantation with 39.0% (n = 166) requiring CPB. There were no differences in demographics and comorbidities, including baseline renal function, between CPB and no CPB. CPB use was higher in recipients with interstitial lung diseases and primary pulmonary hypertension. Median lung allocation score was higher in those needing CPB (47 [interquartile range, 40-59] versus 39 [interquartile range, 35-47]). Patients requiring CPB were significantly more likely to experience AKI (61.44% versus 36.5.3%, P < 0.01) and postoperative hemodialysis (6.6% versus 0.4%, P < 0.01). On multivariable analysis, CPB was significantly associated with postoperative AKI (odds ratio, 1.66; 95% CI, 1.01-2.75; P = 0.04). Thirty-day mortality was higher in patients undergoing CPB (4.2% versus 0.8%, P = 0.03). CONCLUSIONS: CPB for lung transplantation is associated with a higher incidence of AKI, renal failure requiring hemodialysis, and 30-d mortality. CPB should be used selectively for lung transplantation.
BACKGROUND: Cardiopulmonary bypass (CPB) is often used to support patients undergoing lung transplantation who are intolerant of anatomic manipulation or single lung ventilation during the procedure. However, CPB may be associated with adverse outcomes. We evaluated the hypothesis that CPB is associated with increased acute kidney injury (AKI) and postoperative mortality after lung transplantation. MATERIALS AND METHODS: This was a retrospective review of our institutional lung transplant database at the University of Texas Southwestern Medical Center from 2012 to 2018. Patients were grouped based on their need for CPB. The primary outcome was AKI within 48 h of transplantation, which was defined as Kidney Disease Improving Global Outcomes stage 1 or greater. Secondary outcomes included all-cause mortality. RESULTS: A total of 426 patients underwent lung transplantation with 39.0% (n = 166) requiring CPB. There were no differences in demographics and comorbidities, including baseline renal function, between CPB and no CPB. CPB use was higher in recipients with interstitial lung diseases and primary pulmonary hypertension. Median lung allocation score was higher in those needing CPB (47 [interquartile range, 40-59] versus 39 [interquartile range, 35-47]). Patients requiring CPB were significantly more likely to experience AKI (61.44% versus 36.5.3%, P < 0.01) and postoperative hemodialysis (6.6% versus 0.4%, P < 0.01). On multivariable analysis, CPB was significantly associated with postoperative AKI (odds ratio, 1.66; 95% CI, 1.01-2.75; P = 0.04). Thirty-day mortality was higher in patients undergoing CPB (4.2% versus 0.8%, P = 0.03). CONCLUSIONS: CPB for lung transplantation is associated with a higher incidence of AKI, renal failure requiring hemodialysis, and 30-d mortality. CPB should be used selectively for lung transplantation.
Authors: Andrew Chukwuemeka; Ashley Weisel; Manjula Maganti; A Franka Nette; Duminda N Wijeysundera; William S Beattie; Michael A Borger Journal: Ann Thorac Surg Date: 2005-12 Impact factor: 4.330
Authors: J S Gammie; J Cheul Lee; S M Pham; R J Keenan; R J Weyant; B G Hattler; B P Griffith Journal: J Thorac Cardiovasc Surg Date: 1998-05 Impact factor: 5.209
Authors: Tiago N Machuca; Stephane Collaud; Olaf Mercier; Maureen Cheung; Valerie Cunningham; S Joseph Kim; Sassan Azad; Lianne Singer; Kazuhiro Yasufuku; Marc de Perrot; Andrew Pierre; Karen McRae; Thomas K Waddell; Shaf Keshavjee; Marcelo Cypel Journal: J Thorac Cardiovasc Surg Date: 2014-11-21 Impact factor: 5.209
Authors: A Laurie Shroyer; Brack Hattler; Todd H Wagner; Joseph F Collins; Janet H Baltz; Jacquelyn A Quin; G Hossein Almassi; Elizabeth Kozora; Faisal Bakaeen; Joseph C Cleveland; Muath Bishawi; Frederick L Grover Journal: N Engl J Med Date: 2017-08-17 Impact factor: 91.245
Authors: Gavin J Murphy; Barnaby C Reeves; Chris A Rogers; Syed I A Rizvi; Lucy Culliford; Gianni D Angelini Journal: Circulation Date: 2007-11-12 Impact factor: 29.690
Authors: R Aeba; B P Griffith; R L Kormos; J M Armitage; T A Gasior; C R Fuhrman; S A Yousem; R L Hardesty Journal: Ann Thorac Surg Date: 1994-03 Impact factor: 4.330